Patent: 9,896,499
✉ Email this page to a colleague
Summary for Patent: 9,896,499
| Title: | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis |
| Abstract: | The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant. |
| Inventor(s): | Alitalo; Kari (Helsinki, FI), Lemstrom; Karl B. (Helsinki, FI), Nykanen; Antti I. (Helsinki, FI) |
| Assignee: | VEGENICS PTY LIMITED (South Yarra, Victoria, AU) |
| Application Number: | 14/687,556 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,896,499
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2027-02-02 |
| Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2027-02-02 |
| Genzyme Corporation | THYMOGLOBULIN | anti-thymocyte globulin (rabbit) | For Injection | 103869 | 05/19/1999 | ⤷ Try a Trial | 2027-02-02 |
| Biogen Inc. | ZINBRYTA | daclizumab | Injection | 761029 | 05/27/2016 | ⤷ Try a Trial | 2027-02-02 |
| Biogen Inc. | ZINBRYTA | daclizumab | Injection | 761029 | 05/26/2017 | ⤷ Try a Trial | 2027-02-02 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
